Advertisement
ACRS vs QUCY
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACRS is a StrongBuy and QUCY is a Hold.
Momentum Indicator for ACRS turns positive, indicating new upward trend
ACRS saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 92 similar instances where the indicator turned positive. In 80 of the 92 cases, the stock moved higher in the following days. The odds of a move higher are at 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ACRS's RSI Indicator exited the oversold zone, 23 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for ACRS just turned positive on October 21, 2026. Looking at past instances where ACRS's MACD turned positive, the stock continued to rise in 35 of 43 cases over the following month. The odds of a continued upward trend are 81%.
Following a +1.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACRS advanced for three days, in 224 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
ACRS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACRS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for ACRS entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.525) is normal, around the industry mean (2.973). P/E Ratio (-6.603) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (83.333) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. ACRS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
QUCY's RSI Oscillator ascending out of oversold territory
The RSI Oscillator for QUCY moved out of oversold territory on October 13, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 37 similar instances when the indicator left oversold territory. In 34 of the 37 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.65% 3-day Advance, the price is estimated to grow further. Considering data from situations where QUCY advanced for three days, in 150 of 185 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
QUCY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on QUCY as a result. In 105 of 109 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for QUCY turned negative on October 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 35 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
QUCY moved below its 50-day moving average on October 09, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for QUCY crossed bearishly below the 50-day moving average on September 24, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QUCY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for QUCY entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating fairly steady price growth. QUCY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.223) is normal, around the industry mean (64.450). P/E Ratio (-0.634) is within average values for comparable stocks, (2.086). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. QUCY's P/S Ratio (60.976) is very high in comparison to the industry average of (9.775).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QUCY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
ACRS | ||
|---|---|---|
OUTLOOK RATING 1..100 | 8 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 30 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 98 | |
PRICE GROWTH RATING 1..100 | 64 | |
P/E GROWTH RATING 1..100 | 15 | |
SEASONALITY SCORE 1..100 | 27 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| ACRS | QUCY | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 77% | 2 days ago 90% |
| Stochastic ODDS (%) | 1 day ago 89% | 2 days ago 84% |
| Momentum ODDS (%) | 1 day ago 87% | 2 days ago 90% |
| MACD ODDS (%) | 1 day ago 81% | 2 days ago 88% |
| TrendWeek ODDS (%) | 1 day ago 83% | 2 days ago 90% |
| TrendMonth ODDS (%) | 1 day ago 77% | 2 days ago 90% |
| Advances ODDS (%) | 1 day ago 82% | 22 days ago 81% |
| Declines ODDS (%) | 9 days ago 84% | 11 days ago 89% |
| BollingerBands ODDS (%) | 1 day ago 78% | 2 days ago 90% |
| Aroon ODDS (%) | 1 day ago 78% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ACRS’s FA Score shows that 1 FA rating(s) are green while QUCY’s FA Score has 1 green FA rating(s).
- ACRS’s FA Score: 1 green, 4 red.
- QUCY’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ACRS’s TA Score shows that 6 TA indicator(s) are bullish while QUCY’s TA Score has 4 bullish TA indicator(s).
- ACRS’s TA Score: 6 bullish, 2 bearish.
- QUCY’s TA Score: 4 bullish, 6 bearish.
Price Growth
ACRS (@Biotechnology) experienced а +12.72% price change this week, while QUCY (@Medical Specialties) price change was -0.97% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.15%. For the same industry, the average monthly price growth was -6.50%, and the average quarterly price growth was +42.74%.
Reported Earning Dates
ACRS is expected to report earnings on Nov 05, 2026.
QUCY is expected to report earnings on Nov 13, 2026.
Industries' Descriptions
@Biotechnology (-1.10% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Medical Specialties (-3.15% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
ACRS and
Correlation & Price change
A.I.dvisor indicates that over the last year, ACRS has been loosely correlated with CRVS. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if ACRS jumps, then CRVS could also see price increases.
| Ticker / NAME | Correlation To ACRS | 1D Price Change % | ||
|---|---|---|---|---|
| ACRS | 100% | +0.52% | ||
| CRVS - ACRS | 64% Loosely correlated | +5.97% | ||
| STRRP - ACRS | 52% Loosely correlated | +3.16% | ||
| QUCY - ACRS | 40% Loosely correlated | N/A | ||
| UFPT - ACRS | 39% Loosely correlated | +2.49% | ||
| IMNM - ACRS | 38% Loosely correlated | +1.44% | ||
More | ||||
QUCY and
Correlation & Price change
A.I.dvisor indicates that over the last year, QUCY has been loosely correlated with ACRS. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if QUCY jumps, then ACRS could also see price increases.
| Ticker / NAME | Correlation To QUCY | 1D Price Change % | ||
|---|---|---|---|---|
| QUCY | 100% | -4.67% | ||
| ACRS - QUCY | 41% Loosely correlated | +1.06% | ||
| STXS - QUCY | 27% Poorly correlated | -0.34% | ||
| ILMN - QUCY | 25% Poorly correlated | +5.57% | ||
| GH - QUCY | 24% Poorly correlated | +2.50% | ||
| BNGO - QUCY | 23% Poorly correlated | +0.40% | ||
More | ||||